LaserGen Raises $5M; Consulting Firm to Assist on Sequencer Commercialization Plans | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Next-generation sequencing instrument firm LaserGen today announced it has closed its $5 million Series A financing round and signed on a life science consulting firm to assist with commercialization plans.

The $5 million round will be used to demonstrate accurate sequencing of the E. coli genome in the next few months, LaserGen said, and to develop the Baylor College of Medicine spinout's next-generation sequencing system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.